Adverse events associated with diphenhydramine in children, 2008–2015

Robert B. Palmer, Kate M. Reynolds, William Banner, G. Randall Bond, Ralph E. Kauffman, Ian Paul, Jody L. Green, Richard C. Dart

Research output: Contribution to journalArticle

Abstract

Introduction: Diphenhydramine (DPH) exposures in children may be the result of accidental unsupervised ingestions, caregiver error, and intentional misuse of DPH-containing cough and cold medications (CCM). We sought to understand the nature of pediatric ingestions of DPH, particularly the toxicity and outcome of a single product, single ingredient DPH (DPH-only) exposures, in order to derive ingredient-specific information about the clinical effects and course of such cases. Methods: As part of a U.S. multi-year safety surveillance program to assess the safety of over-the-counter (OTC) medications used in cough and cold preparations in children <12 years of age, an expert panel reviewed cases involving symptomatic adverse events potentially related to oral exposures to these medications. After individual review, the cases were categorized by causal relationship of the reported ingredients to the adverse event, exposure intent (therapeutic, non-therapeutic, unknown intent), and dose (therapeutic, supratherapeutic, or unknown). Following panel review, any disagreement on classification was discussed until a consensus was reached. The data were then analyzed with respect to descriptive findings. Results: The panel reviewed 6618 eligible cases and determined 2802 were at least potentially related to oral exposure to DPH. Of these, 2028 were DPH-only cases (39.1% of all cases judged at least potentially related to a cough and cold medication). The majority (79.5%) of DPH-only cases occurred in children 2 to <4 years of age and involved accidental unsupervised ingestions (74.7%). Liquid pediatric formulations were the most common (51.7%) products reported followed by solid pediatric formulations (24.0%). The most common adverse events were tachycardia (53.4%), hallucinations (46.5%), somnolence (34.7%), agitation (33.9%), and mydriasis (26.3%). Seizures occurred in only 5.5% of cases. Five (0.2%) deaths were reported; in the death cases, the DPH dose was judged supratherapeutic in one and unknown in the other four. Child abuse was reported in four of the five death cases and three of the five deaths were homicides. Conclusions: Exposures to DPH-only products were the most common type of exposure detected in our study of adverse events associated with CCM in children. The majority of the DPH-only cases were the result of accidental unsupervised ingestions. Most adverse events were relatively mild self-limited anticholinergic effects and few deaths occurred. Deaths involving DPH were often associated with child abuse or homicide. Interventions targeting the prevention of accidental unsupervised are likely to be impactful in preventing morbidity associated with DPH-only exposure.

Original languageEnglish (US)
JournalClinical Toxicology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Diphenhydramine
Cough
Pediatrics
Eating
Homicide
Child Abuse
Mydriasis
Safety
Hallucinations
Cholinergic Antagonists
Tachycardia
Caregivers
Toxicity

All Science Journal Classification (ASJC) codes

  • Toxicology

Cite this

Palmer, R. B., Reynolds, K. M., Banner, W., Randall Bond, G., Kauffman, R. E., Paul, I., ... Dart, R. C. (2019). Adverse events associated with diphenhydramine in children, 2008–2015. Clinical Toxicology. https://doi.org/10.1080/15563650.2019.1609683
Palmer, Robert B. ; Reynolds, Kate M. ; Banner, William ; Randall Bond, G. ; Kauffman, Ralph E. ; Paul, Ian ; Green, Jody L. ; Dart, Richard C. / Adverse events associated with diphenhydramine in children, 2008–2015. In: Clinical Toxicology. 2019.
@article{7a4d7ac15f3d4334ad858dbea66d3103,
title = "Adverse events associated with diphenhydramine in children, 2008–2015",
abstract = "Introduction: Diphenhydramine (DPH) exposures in children may be the result of accidental unsupervised ingestions, caregiver error, and intentional misuse of DPH-containing cough and cold medications (CCM). We sought to understand the nature of pediatric ingestions of DPH, particularly the toxicity and outcome of a single product, single ingredient DPH (DPH-only) exposures, in order to derive ingredient-specific information about the clinical effects and course of such cases. Methods: As part of a U.S. multi-year safety surveillance program to assess the safety of over-the-counter (OTC) medications used in cough and cold preparations in children <12 years of age, an expert panel reviewed cases involving symptomatic adverse events potentially related to oral exposures to these medications. After individual review, the cases were categorized by causal relationship of the reported ingredients to the adverse event, exposure intent (therapeutic, non-therapeutic, unknown intent), and dose (therapeutic, supratherapeutic, or unknown). Following panel review, any disagreement on classification was discussed until a consensus was reached. The data were then analyzed with respect to descriptive findings. Results: The panel reviewed 6618 eligible cases and determined 2802 were at least potentially related to oral exposure to DPH. Of these, 2028 were DPH-only cases (39.1{\%} of all cases judged at least potentially related to a cough and cold medication). The majority (79.5{\%}) of DPH-only cases occurred in children 2 to <4 years of age and involved accidental unsupervised ingestions (74.7{\%}). Liquid pediatric formulations were the most common (51.7{\%}) products reported followed by solid pediatric formulations (24.0{\%}). The most common adverse events were tachycardia (53.4{\%}), hallucinations (46.5{\%}), somnolence (34.7{\%}), agitation (33.9{\%}), and mydriasis (26.3{\%}). Seizures occurred in only 5.5{\%} of cases. Five (0.2{\%}) deaths were reported; in the death cases, the DPH dose was judged supratherapeutic in one and unknown in the other four. Child abuse was reported in four of the five death cases and three of the five deaths were homicides. Conclusions: Exposures to DPH-only products were the most common type of exposure detected in our study of adverse events associated with CCM in children. The majority of the DPH-only cases were the result of accidental unsupervised ingestions. Most adverse events were relatively mild self-limited anticholinergic effects and few deaths occurred. Deaths involving DPH were often associated with child abuse or homicide. Interventions targeting the prevention of accidental unsupervised are likely to be impactful in preventing morbidity associated with DPH-only exposure.",
author = "Palmer, {Robert B.} and Reynolds, {Kate M.} and William Banner and {Randall Bond}, G. and Kauffman, {Ralph E.} and Ian Paul and Green, {Jody L.} and Dart, {Richard C.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/15563650.2019.1609683",
language = "English (US)",
journal = "Clinical Toxicology",
issn = "1556-3650",
publisher = "Informa Healthcare",

}

Palmer, RB, Reynolds, KM, Banner, W, Randall Bond, G, Kauffman, RE, Paul, I, Green, JL & Dart, RC 2019, 'Adverse events associated with diphenhydramine in children, 2008–2015' Clinical Toxicology. https://doi.org/10.1080/15563650.2019.1609683

Adverse events associated with diphenhydramine in children, 2008–2015. / Palmer, Robert B.; Reynolds, Kate M.; Banner, William; Randall Bond, G.; Kauffman, Ralph E.; Paul, Ian; Green, Jody L.; Dart, Richard C.

In: Clinical Toxicology, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adverse events associated with diphenhydramine in children, 2008–2015

AU - Palmer, Robert B.

AU - Reynolds, Kate M.

AU - Banner, William

AU - Randall Bond, G.

AU - Kauffman, Ralph E.

AU - Paul, Ian

AU - Green, Jody L.

AU - Dart, Richard C.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Diphenhydramine (DPH) exposures in children may be the result of accidental unsupervised ingestions, caregiver error, and intentional misuse of DPH-containing cough and cold medications (CCM). We sought to understand the nature of pediatric ingestions of DPH, particularly the toxicity and outcome of a single product, single ingredient DPH (DPH-only) exposures, in order to derive ingredient-specific information about the clinical effects and course of such cases. Methods: As part of a U.S. multi-year safety surveillance program to assess the safety of over-the-counter (OTC) medications used in cough and cold preparations in children <12 years of age, an expert panel reviewed cases involving symptomatic adverse events potentially related to oral exposures to these medications. After individual review, the cases were categorized by causal relationship of the reported ingredients to the adverse event, exposure intent (therapeutic, non-therapeutic, unknown intent), and dose (therapeutic, supratherapeutic, or unknown). Following panel review, any disagreement on classification was discussed until a consensus was reached. The data were then analyzed with respect to descriptive findings. Results: The panel reviewed 6618 eligible cases and determined 2802 were at least potentially related to oral exposure to DPH. Of these, 2028 were DPH-only cases (39.1% of all cases judged at least potentially related to a cough and cold medication). The majority (79.5%) of DPH-only cases occurred in children 2 to <4 years of age and involved accidental unsupervised ingestions (74.7%). Liquid pediatric formulations were the most common (51.7%) products reported followed by solid pediatric formulations (24.0%). The most common adverse events were tachycardia (53.4%), hallucinations (46.5%), somnolence (34.7%), agitation (33.9%), and mydriasis (26.3%). Seizures occurred in only 5.5% of cases. Five (0.2%) deaths were reported; in the death cases, the DPH dose was judged supratherapeutic in one and unknown in the other four. Child abuse was reported in four of the five death cases and three of the five deaths were homicides. Conclusions: Exposures to DPH-only products were the most common type of exposure detected in our study of adverse events associated with CCM in children. The majority of the DPH-only cases were the result of accidental unsupervised ingestions. Most adverse events were relatively mild self-limited anticholinergic effects and few deaths occurred. Deaths involving DPH were often associated with child abuse or homicide. Interventions targeting the prevention of accidental unsupervised are likely to be impactful in preventing morbidity associated with DPH-only exposure.

AB - Introduction: Diphenhydramine (DPH) exposures in children may be the result of accidental unsupervised ingestions, caregiver error, and intentional misuse of DPH-containing cough and cold medications (CCM). We sought to understand the nature of pediatric ingestions of DPH, particularly the toxicity and outcome of a single product, single ingredient DPH (DPH-only) exposures, in order to derive ingredient-specific information about the clinical effects and course of such cases. Methods: As part of a U.S. multi-year safety surveillance program to assess the safety of over-the-counter (OTC) medications used in cough and cold preparations in children <12 years of age, an expert panel reviewed cases involving symptomatic adverse events potentially related to oral exposures to these medications. After individual review, the cases were categorized by causal relationship of the reported ingredients to the adverse event, exposure intent (therapeutic, non-therapeutic, unknown intent), and dose (therapeutic, supratherapeutic, or unknown). Following panel review, any disagreement on classification was discussed until a consensus was reached. The data were then analyzed with respect to descriptive findings. Results: The panel reviewed 6618 eligible cases and determined 2802 were at least potentially related to oral exposure to DPH. Of these, 2028 were DPH-only cases (39.1% of all cases judged at least potentially related to a cough and cold medication). The majority (79.5%) of DPH-only cases occurred in children 2 to <4 years of age and involved accidental unsupervised ingestions (74.7%). Liquid pediatric formulations were the most common (51.7%) products reported followed by solid pediatric formulations (24.0%). The most common adverse events were tachycardia (53.4%), hallucinations (46.5%), somnolence (34.7%), agitation (33.9%), and mydriasis (26.3%). Seizures occurred in only 5.5% of cases. Five (0.2%) deaths were reported; in the death cases, the DPH dose was judged supratherapeutic in one and unknown in the other four. Child abuse was reported in four of the five death cases and three of the five deaths were homicides. Conclusions: Exposures to DPH-only products were the most common type of exposure detected in our study of adverse events associated with CCM in children. The majority of the DPH-only cases were the result of accidental unsupervised ingestions. Most adverse events were relatively mild self-limited anticholinergic effects and few deaths occurred. Deaths involving DPH were often associated with child abuse or homicide. Interventions targeting the prevention of accidental unsupervised are likely to be impactful in preventing morbidity associated with DPH-only exposure.

UR - http://www.scopus.com/inward/record.url?scp=85065544683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065544683&partnerID=8YFLogxK

U2 - 10.1080/15563650.2019.1609683

DO - 10.1080/15563650.2019.1609683

M3 - Article

JO - Clinical Toxicology

JF - Clinical Toxicology

SN - 1556-3650

ER -